Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels

Strahlentherapie und Onkologie

Volumn 184, Issue 1, 2008, Pages 1-7

  Lövey, József ^a   Bereczky, Bíborka ^a   Gilly, Réka ^a   Kenessey, István ^a   Rásó, Erzsébet ^a   Simon, Erika ^a   Dobos, Judit ^a,b   Vágó, Ágnes ^a   Kásler, Miklós ^a   Döme, Balázs ^b   Tímár, József ^a   Tóvári, József ^b,c  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Human squamous cell carcinoma; Radiation therapy; Recombinant human erythropoietin alpha; Tumor xenograft model; Tumor induced angiogenesis

Indexed keywords

COMPLEMENTARY DNA; DNA; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT ERYTHROPOIETIN; RNA;

ANEMIA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR XENOGRAFT; X IRRADIATION;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RADIATION-SENSITIZING AGENTS; SOFT TISSUE NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 38149063793     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-1745-2     Document Type: Article

References (45)

1. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
2. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-806.
3. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-82.
4. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999-1007.
5. Batra S, Perelman N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-87.
6. Blohmer JU, Wurschmidt U, Petry G. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-Intergroup study: sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high risk cervical cancer. Proc Am Soc Clin Oncol 2003;22:447.
7. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Sci 2006;98:708-14.
8. FDA Alert. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Rockville: Food and Drug Administration, March 9, 2007 (http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm, accessed May 25, 2007).
9. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia inducible factor 1. Mol Cell Biol 1996;16:4604-13.
10. Garcia-Baross M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
11. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
12. Henke M, Laszing R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;36:1255-60.
13. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13.
14. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation and chemotherapy. Cancer Res 2005;65:3643-55.
15. Ishikawa H, Sakurai H, Hasegawa M, et al. Expression of hypoxia-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004;60:513-21.
16. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-33.
17. Kirkpatrick JP, Hardee ME, Snyder SA, et al. The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 2006;165:192-201.
18. Laveys RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 1998;174:Suppl 4:24-30.
19. Leo C, Horn LC, Rauscher C, et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. J Clin Cancer 2006;12:6894-900.
20. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2004;8:459-60.
21. Lövey J, Lukits J, Remenár E, et al. Antiangiogenic effects of radiotherapy but not initial microvessel density predict survival in inoperable oropharyngeal squamous cell carcinoma. Strahlenther Onkol 2006;182:149-56.
22. Ludwig H. rHuEPO and treatment outcomes: the preclinical experience. Oncologist 2004;9:48-54.
23. Marinaccio M, Mele E, Giotta F. Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients. Proc Am Soc Clin Oncol 2003;22:486.
24. Marshall DJ, Tullai J, Gechtman Z, et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006;5:347-55.
25. Mayer R, Hamilton-Farrell MR, van der Kleij AJ, et al. Hyperbaric oxygen and radiotherapy. Strahlenther Onkol 2005;181:113-23.
26. Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals and stress granules. Cancer Cell 2004;5:429-41.
27. Molls M, Stadler P, Becker A, et al. Relevance of oxygen in radiation oncology. Mechanism of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998;74:Suppl 4:13-6.
28. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293:293-7.
29. Rades D, Schulte R, Yekebas EF, et al. Radio(chemo)therapy plus resection versus radio(chemo)therapy alone for the treatment of stage III esophageal cancer. Strahlenther Onkol 2007;183:10-6.
30. Rades D, Tribius S, Yekebas EF, et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat Oncol Biol Phys 2006;65:459-65.
31. Reichel O, Panzer M, Wimmer C, et al. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiotherapy for head and neck tumors. Eur Arch Otorhinolaryngol 2003;260:248-53.
32. Ribatti D, Marzullo A, Nico B, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
33. Rohrer Bley C, Ohlerth S, Roos M, et al. Influence of pretreatment polarographically measured oxygenation levels in spontaneous canine tumors treated with radiation therapy. Strahlenther Onkol 2006;182:518-24.
34. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
35. Stasi R, Amadori S, Littlewood TJ, et al. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 2005;10:539-54.
36. Stüben G, Thews O, Pöttgen C, et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-5.
37. Tchekmedyian NS. Anaemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002;1:17-24.
38. Temkin SM, Hellmann M, Serur E, et al. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer 2006;16:1855-61.
39. Tóvári J, Gilly R, Rásó E, et al. Recombinant human erythropoietin alpha targets intratumoral blood vessels improving chemotherapy in human xenograft models. Cancer Res 2005;65:7186-93.
40. Vaupel P, Kelleher DK, Höckel M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
41. Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71.
42. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors. Med Oncol 2001;18:243-59.
43. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
44. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001;84:836-43.
45. Zips D, Eichler W, Geyer P, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 2005;65:5374-9.